Kalobios Pharmaceuticals Inc (KBIO) 1.85 $KBIO
KaloBios (KBIO) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 6:58AM CDT
KaloBios (KBIO) is now in Oversold Territory
KaloBios Provides First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced financial results for the first quarter of 2014 and provided an update on its current clinical programs and timelines.
Ted W. Love, M.D., Named Chairman of the Board of KaloBios
PR Newswire - Tue May 06, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company's board of directors has elected Ted W. Love, M.D., as the Chairman, effective May 1, 2014. Dr. Love succeeds James I. Healy, M.D., Ph.D., who had served as a member of the board of directors and as chairman of the board since 2001. Dr. Healy recently informed KaloBios that in light of the company's public offering in 2013 and his other present and potential public company board commitments, he did not intend to stand for re-election to the KaloBios board of directors at the upcoming annual meeting of stockholders, scheduled for June 18, 2014.
KaloBios Announces Upcoming Participation at Needham Healthcare Conference
PR Newswire - Thu Apr 03, 6:30PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference:
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
How KaloBios (KBIO) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:33AM CDT
KaloBios is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 9 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
KaloBios Announces Fiscal Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on corporate accomplishments in fiscal 2013 and key milestones for 2014 as well as announcing financial results for fiscal year 2013.
KaloBios Announces Upcoming Participation at ROTH and BioCentury's Future Leaders in the Biotech Industry Conferences
PR Newswire - Mon Mar 10, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences:
Envestnet President Bill Crager To Chair Panel At ABA Wealth Management And Trust Conference
PR Newswire - Wed Feb 26, 7:45AM CST
Envestnet, Inc. (NYSE: ENV), a leading provider of integrated wealth management technology and services to investment advisors and wealth managers, announces that President Bill Crager will moderate a panel discussion at the American Bankers Association (ABA) Wealth Management and Trust Conference, which will take place from February 26-28, 2014 at the Hilton San Diego Bayfront Hotel.
InMobi Partners with Top Football News Publisher, Adversport's Foot Mercato
PR Newswire - Wed Feb 26, 7:17AM CST
InMobi, the world's largest independent mobile advertising company, today announced an exclusive partnership agreement with Adversport, the publisher of Foot Mercato, the leading football app on the App Store. InMobi has been selected as the exclusive mobile advertising platform for Adversport's mobile and tablet properties across France (Foot Mercato), Germany (Fussballtransfer) and Spain (Fichajes).
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech - 2014 Edition
M2 - Mon Feb 17, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/h484j7/discovery_stage) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma and Biotech" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 4,000 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Companies Mentioned: - Abbott - Actavis - Bristol-Myers Squibb - Celgene - Daiichi Sankyo - Elan - Eli Lilly - Fresenius Biotech - GE Healthcare - GlycArt - ImmunoGen - Intrexon - Johnson & Johnson - KaloBios Pharmaceuticals - Lpath - Lundbeck - Macrogenics - Merck & Co - Novo Nordisk - Orbimed Advisors - Peregrine Pharmaceuticals - Pfizer - RIT Oncology - Seattle Genetics - TrovaGene - TTFactor - University of Texas - Wyeth - Xencor - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/h4...very_stage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myeloproliferative Disorders - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 11, 9:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rhjv83/myeloproliferative) has announced the addition of the "Myeloproliferative Disorders - Pipeline Review, H2 2013" report to their offering. 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Scope - A snapshot of the global therapeutic scenario for Myeloproliferative Disorders. - A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Myeloproliferative Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Myeloproliferative Disorders - Products under Development by Companies Myeloproliferative Disorders - Products under Investigation by Universities/Institutes Myeloproliferative Disorders - Companies Involved in Therapeutics Development Myeloproliferative Disorders - Therapeutics Assessment Triapine - Drug Profile givinostat - Drug Profile ganetespib - Drug Profile KB-004 - Drug Profile gandotinib - Drug Profile EPZ-5676 - Drug Profile ON-044580 - Drug Profile Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms - Drug Profile Kinase Inhibitors for Oncology - Drug Profile Small Molecule To Inhibit JAK2 For Myeloproliferative Disorder - Drug Profile AG-120 - Drug Profile CPL-407-22 - Drug Profile Jak2 Inhibitors - Drug Profile Featured News & Press Releases Companies Mentioned Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. Nanotherapeutics, Inc. Synta Pharmaceuticals Corp. Italfarmaco S.p.A. Celon Pharma Sp. z o.o. Agios Pharmaceuticals, Inc. Onconova Therapeutics, Inc. KaloBios Pharmaceuticals, Inc. EpiZyme, Inc. For more information visit http://www.researchandmarkets.com/research/rh...liferative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies
PR Newswire - Tue Feb 11, 7:00AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company's anti-EphA3 Humaneered® monoclonal antibody (mAb). The company is targeting enrollment of 30 patients for this portion of the Phase 2 expansion focusing solely on patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are prescreened prior to treatment for EphA3 positivity. EphA3 is a tyrosine kinase receptor that is highly expressed on malignant stem cells in different hematological and solid tumors.
KaloBios Announces Upcoming Webcasts and Conference Participation
PR Newswire - Wed Feb 05, 5:00PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences:
KaloBios (KBIO) Crumbles: Stock Falls by 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 7:46AM CST
KaloBios Pharmaceuticals, Inc. (KBIO) saw a big move last session, as the company’s shares fell by more than 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for KBIO, as the stock is now down about 42% since Jan 15.
KaloBios to Stop KB003 Development for Asthma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 5:50PM CST
KaloBios announced disappointing results from a phase II study on KB003 in patients suffering from severe asthma.
KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma
PR Newswire - Wed Jan 29, 3:01PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the completion of the randomized, double-blind placebo-controlled Phase 2 study of KB003, its anti-GM-CSF monoclonal antibody (mAb), in patients with severe asthma. While the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV1 (a measurement of pulmonary function) compared to placebo in the overall study population.
Epidemiological Study on Ventilator-Associated Pneumonia Incidence Reported at Critical Care Congress, Announces KaloBios
PR Newswire - Mon Jan 13, 7:00AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the presentation of epidemiological research sponsored by Sanofi Pasteur, KaloBios' exclusive licensee for KB001-A, estimating the incidence of Pseudomonas aeruginosa Ventilator Associated Pneumonia (Pa-VAP) in at-risk patients requiring intubation and mechanical ventilation. The presentation also describes the risk factors among patients with VAP and Pa-VAP. The new research found similar risk factors and infection rates for VAP across multiple global regions. Moreover, the study results suggest that mechanically ventilated patients who are colonized with Pa are at increased risk of developing Pa-VAP. Sanofi Pasteur is developing KB001-A, KaloBios' anti-PcrV monoclonal antibody (mAb) fragment against Pa for the prevention of Pa--VAP, in the intensive-care setting.
KaloBios Pharmaceuticals Inc names Dr Harry Lam as head of Manufacturing
M2 - Wed Jan 08, 5:54AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals Inc (NasdaqGM:KBIO) revealed on Tuesday that it has elected Dr Harry Lam, PhD as head of Manufacturing.
KaloBios (KBIO) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 6:58AM CDT
KaloBios (KBIO) is now in Oversold Territory
KaloBios Provides First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced financial results for the first quarter of 2014 and provided an update on its current clinical programs and timelines.
Ted W. Love, M.D., Named Chairman of the Board of KaloBios
PR Newswire - Tue May 06, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company's board of directors has elected Ted W. Love, M.D., as the Chairman, effective May 1, 2014. Dr. Love succeeds James I. Healy, M.D., Ph.D., who had served as a member of the board of directors and as chairman of the board since 2001. Dr. Healy recently informed KaloBios that in light of the company's public offering in 2013 and his other present and potential public company board commitments, he did not intend to stand for re-election to the KaloBios board of directors at the upcoming annual meeting of stockholders, scheduled for June 18, 2014.
KaloBios Announces Upcoming Participation at Needham Healthcare Conference
PR Newswire - Thu Apr 03, 6:30PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference:
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
How KaloBios (KBIO) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:33AM CDT
KaloBios is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 9 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
KaloBios Announces Fiscal Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on corporate accomplishments in fiscal 2013 and key milestones for 2014 as well as announcing financial results for fiscal year 2013.
KaloBios Announces Upcoming Participation at ROTH and BioCentury's Future Leaders in the Biotech Industry Conferences
PR Newswire - Mon Mar 10, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences:
Envestnet President Bill Crager To Chair Panel At ABA Wealth Management And Trust Conference
PR Newswire - Wed Feb 26, 7:45AM CST
Envestnet, Inc. (NYSE: ENV), a leading provider of integrated wealth management technology and services to investment advisors and wealth managers, announces that President Bill Crager will moderate a panel discussion at the American Bankers Association (ABA) Wealth Management and Trust Conference, which will take place from February 26-28, 2014 at the Hilton San Diego Bayfront Hotel.
InMobi Partners with Top Football News Publisher, Adversport's Foot Mercato
PR Newswire - Wed Feb 26, 7:17AM CST
InMobi, the world's largest independent mobile advertising company, today announced an exclusive partnership agreement with Adversport, the publisher of Foot Mercato, the leading football app on the App Store. InMobi has been selected as the exclusive mobile advertising platform for Adversport's mobile and tablet properties across France (Foot Mercato), Germany (Fussballtransfer) and Spain (Fichajes).
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech - 2014 Edition
M2 - Mon Feb 17, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/h484j7/discovery_stage) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma and Biotech" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 4,000 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Companies Mentioned: - Abbott - Actavis - Bristol-Myers Squibb - Celgene - Daiichi Sankyo - Elan - Eli Lilly - Fresenius Biotech - GE Healthcare - GlycArt - ImmunoGen - Intrexon - Johnson & Johnson - KaloBios Pharmaceuticals - Lpath - Lundbeck - Macrogenics - Merck & Co - Novo Nordisk - Orbimed Advisors - Peregrine Pharmaceuticals - Pfizer - RIT Oncology - Seattle Genetics - TrovaGene - TTFactor - University of Texas - Wyeth - Xencor - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/h4...very_stage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myeloproliferative Disorders - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 11, 9:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rhjv83/myeloproliferative) has announced the addition of the "Myeloproliferative Disorders - Pipeline Review, H2 2013" report to their offering. 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Scope - A snapshot of the global therapeutic scenario for Myeloproliferative Disorders. - A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Myeloproliferative Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Myeloproliferative Disorders - Products under Development by Companies Myeloproliferative Disorders - Products under Investigation by Universities/Institutes Myeloproliferative Disorders - Companies Involved in Therapeutics Development Myeloproliferative Disorders - Therapeutics Assessment Triapine - Drug Profile givinostat - Drug Profile ganetespib - Drug Profile KB-004 - Drug Profile gandotinib - Drug Profile EPZ-5676 - Drug Profile ON-044580 - Drug Profile Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms - Drug Profile Kinase Inhibitors for Oncology - Drug Profile Small Molecule To Inhibit JAK2 For Myeloproliferative Disorder - Drug Profile AG-120 - Drug Profile CPL-407-22 - Drug Profile Jak2 Inhibitors - Drug Profile Featured News & Press Releases Companies Mentioned Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. Nanotherapeutics, Inc. Synta Pharmaceuticals Corp. Italfarmaco S.p.A. Celon Pharma Sp. z o.o. Agios Pharmaceuticals, Inc. Onconova Therapeutics, Inc. KaloBios Pharmaceuticals, Inc. EpiZyme, Inc. For more information visit http://www.researchandmarkets.com/research/rh...liferative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies
PR Newswire - Tue Feb 11, 7:00AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company's anti-EphA3 Humaneered® monoclonal antibody (mAb). The company is targeting enrollment of 30 patients for this portion of the Phase 2 expansion focusing solely on patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are prescreened prior to treatment for EphA3 positivity. EphA3 is a tyrosine kinase receptor that is highly expressed on malignant stem cells in different hematological and solid tumors.
KaloBios Announces Upcoming Webcasts and Conference Participation
PR Newswire - Wed Feb 05, 5:00PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences:
KaloBios (KBIO) Crumbles: Stock Falls by 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 7:46AM CST
KaloBios Pharmaceuticals, Inc. (KBIO) saw a big move last session, as the company’s shares fell by more than 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for KBIO, as the stock is now down about 42% since Jan 15.
KaloBios to Stop KB003 Development for Asthma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 5:50PM CST
KaloBios announced disappointing results from a phase II study on KB003 in patients suffering from severe asthma.
KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma
PR Newswire - Wed Jan 29, 3:01PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the completion of the randomized, double-blind placebo-controlled Phase 2 study of KB003, its anti-GM-CSF monoclonal antibody (mAb), in patients with severe asthma. While the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV1 (a measurement of pulmonary function) compared to placebo in the overall study population.
Epidemiological Study on Ventilator-Associated Pneumonia Incidence Reported at Critical Care Congress, Announces KaloBios
PR Newswire - Mon Jan 13, 7:00AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the presentation of epidemiological research sponsored by Sanofi Pasteur, KaloBios' exclusive licensee for KB001-A, estimating the incidence of Pseudomonas aeruginosa Ventilator Associated Pneumonia (Pa-VAP) in at-risk patients requiring intubation and mechanical ventilation. The presentation also describes the risk factors among patients with VAP and Pa-VAP. The new research found similar risk factors and infection rates for VAP across multiple global regions. Moreover, the study results suggest that mechanically ventilated patients who are colonized with Pa are at increased risk of developing Pa-VAP. Sanofi Pasteur is developing KB001-A, KaloBios' anti-PcrV monoclonal antibody (mAb) fragment against Pa for the prevention of Pa--VAP, in the intensive-care setting.
KaloBios Pharmaceuticals Inc names Dr Harry Lam as head of Manufacturing
M2 - Wed Jan 08, 5:54AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals Inc (NasdaqGM:KBIO) revealed on Tuesday that it has elected Dr Harry Lam, PhD as head of Manufacturing.
